Policy
FDA's peptide compounding policy
We follow the FDA policies that change what clinics and pharmacies can sell. The peptide compounding policy has been under White House review since Oct. 14.
FDA's interim policy on compounded peptides
The American Academy of Peptide Medicine meets the White House on Wednesday, Oct. 21. Hims & Hers meets the White House on Friday, Oct. 23.